치료저항성 정신분열증 환자의 Haloperidol과 Carbamazepine 병합투여 치료효과

Efficacy of Haloperidol and Carbamazepine Combination in Treatment-Resistent Schizophrenia

The purpose of this study were to see the clinical effect of haloperidol and carbamazepine combination in treatment-resistant schizopherenia and to see whether carbamazepine has any impact on the plasma concentration of haloperidol. Carbamazepine (mean =115Omg/day) is administrated to 30 treatment-resistant schizophrenic patients, and among them 18 patients dropped out because of the side effects. There was significant improvement in the negative scale (p = 0.003)，especially on blunted affect and lack of spontaneity and flow of conversation subscales of PANSS. The mean concentration of carbamazepine have decreased on the fourth week (p = 0.002)，and the mean plasma concentration of haloperidol has decreased (mean=26. 83%) on the second and fourth week of the study (p = 0.001). However, we could not find any correlation of between the decreasing plasma concentration of haloperidol by administering carbamazepine and clinical effect. As a conclusion, the adjunctive treatment of carbamazepine to haloperidol in the treatment-resistant schizophrenia has improved in negative schizophrenic symptoms rather than in the positive symptoms. This suggests the usefulness of adjunctive treatment in terms of improving the overall quality of the life of the treatment-resistant schizophrenic patients